GLP-1/GIP/glucagon receptor agonist (obesity)

未知生产厂商

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

NOVEL TRIPLE GLP-1/GIP/GLUCAGON RECEPTOR AGONIST AND A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING THE SAME
申请人: HANMI PHARMACEUTICAL CO LTD优先权: 2022
CN
US
2 件公开
COMPOSITIONS AND METHODS FOR TREATING OBESITY AND DIABETES USING 15-PGDH INHIBITORS
申请人: EPIRIUM BIO INC优先权: 2024
WO
TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS
申请人: ANTAG THERAPEUTICS APS优先权: 2021
CN
US
2 件公开
GLP-1R/GIPR/GCGR triple receptor agonist and application thereof
申请人: SHANGHAI INST OF BIOLOGICAL PRODUCTS CO LTD优先权: 2026
CN
GLP-1 and GIP dual agonist fusion proteins
申请人: SHANGHAI MINWEI BIOTECHNOLOGY CO LTD优先权: 2023
CN
Dual-agonist compound for both GLP-1 and GIP receptors and application thereof
申请人: JIANGSU HENGRUI PHARMACEUTICALS CO LTD优先权: 2020
CN
EP
US
WO
7 件公开
PIPERIDINE UREA DERIVATIVES FOR OBESITY THERAPY
申请人: ASTRIZI BIO INC优先权: 2024
US
WO
2 件公开
INCRETIN ANALOG AND USE THEREOF
申请人: SHANGHAI MINWEI BIOTECHNOLOGY CO LTD优先权: 2023
CN
EP
US
WO
4 件公开